Colorectal Cancer: Anvisa-approved drug study has unprecedented results in tumor removal in 100% of cases. “During the average 12-month period, no patient received chemoradiotherapy and no patient underwent surgical resection.”
A drug already approved by Anvisa shocked the scientific community by eliminating colorectal cancer in 100% of patients undergoing treatment. The test that validated the startling research came from a small group of 12 patients with rectal cancer. In them, the researchers applied a monoclonal antibody called dostarlimab locally, which resulted in an encouraging result and lasted for more than a year.
The study was published in the New England Journal of Medicine on Sunday the 5th and was discussed by oncologists during the American Society of Clinical Oncology (ASCO) annual event, which ended on Tuesday, the 7th. examinations such as MRI imaging, endoscopic evaluation, digital rectal examination, or biopsy showed no evidence of the presence of a tumor.
Patients took the drug intravenously every three weeks for six months. “During the average 12-month follow-up period, no patients received chemoradiotherapy and no patients underwent surgical resection,” says a study excerpt.
In an interview with The New York Times, oncologist Luiz Diaz Jr., one of the authors of the paper, says that the success rate of American research is unusual, and perhaps this is the first time such a thing has happened. is recorded throughout the country.the history of cancer studies.
“I don’t think anyone has seen this before, where all patients had the tumor go away,” said oncologist at Memorial Sloan Kettering Cancer Center in New York and lead author of the study Andrea Cercek.
Dostarlimab is approved in Brazil to treat endometrial cancer and had not been tested for other tumors until then. While promising, the study has some caveats, such as the need for long-term follow-up to see if tumors will not re-emerge or if metastases will not appear in other parts of the body.
It is also worth noting that all the volunteers carried a specific abnormality in their rectal cancer, popularly known as ‘mismatch repair deficiency’, which prevents the body’s function from normalizing and producing cellular mutations. This type of abnormality occurs in between 5 and 10% of all patients with rectal cancer.
Patients with rectal cancer have a high survival rate, but conventional treatment can leave lifelong sequelae. Some examples of sequelae are: intestinal and bladder dysfunction, sexual dysfunction, and even infertility in younger women. Some patients may still need to carry a colostomy bag permanently.
→ IF YOU DID IT HERE … Consider helping Pragmatism continue the work it has been doing for 13 years, reaching millions. Our journalism has always bothered a lot of people, but attempts to silence it have intensified since Jair Bolsonaro came to power. So it never made sense to ask for your support. Any input is important and helps maintain the team, structure and freedom of expression. Click here and support!